Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1

Journal of Endocrinological Investigation

Volumn 24, Issue 1, 2001, Pages 37-41

  Martina, V ^a   Bruno, G A ^a   Zumpano, E ^a   Origlia, C ^a   Quaranta, L ^a   Pescarmona, G P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

cNOS activity; Glutathione; Nitric oxide; PAI 1; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLUTATHIONE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ERYTHROCYTE LEVEL; FEMALE; HUMAN; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE FUNCTION;

AGED; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1; UMBILICAL VEINS;

EID: 0035117433     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343806     Document Type: Article

References (39)

1. Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
2. Endothelial disfunction in diabetes mellitus
3. Diabetes mellitus and vascular lesions
4. Dyslipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: An hypothesis
5. Nitric oxide availability in diabetes mellitus
6. Review of alterations in endothelial nitric oxide production in diabetes: Protective role of arginine on endothelial disfunction
7. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration
8. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells
9. Endothelium derived relaxing factor: Identification as nitric oxide and role in the control of vascular tone and platelet function
10. Different activation of the endothelial L-arginine and ciclooxygenase pathway in the human internal mammary artery and saphenous vein
11. Platelet cNOS activity is reduced in patients with IDDM and NIDDM
12. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients
13. Acute amelioration of diabetic endothelial disfunction with a derivative of nitric oxide sinthase cofactor, tetrahydrobiopterin
14. A nitric oxide synthesis is impaired in GSH depleted human umbilical vein endothelial cells
15. Shortened red cell life span in diabetes: Mechanism of haemolysis
16. Impairment of GSH metabolism in erytrocytes from patients with diabetes mellitus
17. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of GSH synthesis and efflux
18. Platelet glutathione and thromboxane synthesis in diabetes
19. 2+/EDRF signalling is due to generation of superoxide anions
20. Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycaemia
21. Red cell metabolism
22. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-hosed enzyme-linked immunosorbent assay
23. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma
24. Role of glutathione in blood platelet function
25. Effect of GSH depletion by 1-chloro-2,4-dinitrobenzene on human platelet aggregation, arachidonic acid oxidative metabolism and cytoskeletal proteins
26. ++ influx
27. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: Evidence of inhibition of thromboxane A2 synthesis in human blood platelets
28. 2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production
29. 2+/cGMP response scavenging superoxide anions
30. Activation of soluble guanylate cyclase by nitrovasodilators is inhibited by oxidized low-density lipoprotein
31. Inhibition of platelet activation by 2-mercaptopropionylglycin in vitro and in vivo
32. In vitro-effect of reduced glutathione on platelet function
33. PAI-1 reduction after treatment with GSH in NIDDM
34. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
35. Hypofibrinolysis associated with vasculopathy in non-insulin-dependent diabetes mellitus
36. Fibrinolysis
37. The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats
38. The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro
39. Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells